Advertisement

Pharmacy World & Science

, Volume 30, Issue 6, pp 753–758 | Cite as

Five-year follow-up of drug utilization for secondary prevention in coronary artery disease

  • Sule Apikoglu Rabus
  • Fikret V. Izzettin
  • Mesut Sancar
  • Osman Karakaya
  • Ramazan Kargin
  • Cevat Yakut
Short Research Report

Abstract

Objective Despite the availability of various prevention guidelines on coronary artery disease, secondary prevention practice utilizing aspirin, beta-blockers, angiotensin converting enzyme inhibitors and statins still can be sub-optimal. In this study, we aimed to assess the guideline adherence of secondary prevention prescribing and the continuity of adherence for a 5-year period in a small cohort of patients angiographically diagnosed to have coronary artery disease. Method In this prospective study, 73 patients who were angiographically diagnosed to have CAD were followed up for 5 years. The baseline demographic and clinical data were collected just before angiography. The baseline drug data were collected at the day of discharge. The fifth year data were taken from the patients via face-to-face consultations or phone interviews. Results The ‘initial prescribing rate’ at discharge was found to be 82% for aspirin, 49% for statins, 44% for ACE inhibitors and 55% for beta-blockers. ‘Continuity of prescribing’ for 5 years was 45% for aspirin, 26% for statins, 17% for ACE inhibitors and 20% for beta-blockers. Conclusions Besides the sub-optimal prescribing of secondary prevention drugs, absence of continuity of prescribing seems to be a challenging issue in pharmaceutical care of coronary artery disease patients.

Keywords

Drug Utilisation Follow up Guideline Secondary prevention Coronary disease Turkey 

Notes

Funding

The study was carried out with no external funding.

Conflict of interest

The authors have no conflicts of interest.

References

  1. 1.
    AHA; ACC; National Heart, Lung, and Blood Institute, Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–9.Google Scholar
  2. 2.
    Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007;194:1–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Chinwong S, Reid F, McGlynn S, Hudson SA, Flapan AD. The need for pharmaceutical care in the prevention of coronary heart disease: an exploratory study in acute myocardial infarction patients. Pharm World Sci. 2004;26:96–101.PubMedCrossRefGoogle Scholar
  4. 4.
    Reid F, Fossland B, Flapan AD, Duckelmann CC, Hudson SA. Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction. Pharm World Sci. 2001;23:177–8.PubMedCrossRefGoogle Scholar
  5. 5.
    World Health Organization. World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999.Google Scholar
  6. 6.
    EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–72.CrossRefGoogle Scholar
  7. 7.
    Wahl C, Gregoire JP, Teo K, Beaulieu M, Labelle S, Leduc B, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Q. 2005;8:65–70.PubMedGoogle Scholar
  8. 8.
    Montague T, Sidel J, Erhardt B, Nakhlé G, Caron L, Croteau D, et al. Patient health management: a promising paradigm in Canadian healthcare. Am J Manag Care. 1997;3:1175–82.PubMedGoogle Scholar
  9. 9.
    Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Al-Rashed SA, Wright DJ, Roebuck N, Sunter W, Chrystyn H. The value of inpatient pharmaceutical counselling to elderly patients prior to discharge. Br J Clin Pharmacol. 2002;54:657–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458–65.PubMedCrossRefGoogle Scholar
  12. 12.
    Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ. 1998;317:465–8.PubMedGoogle Scholar
  13. 13.
    Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):1–72.Google Scholar
  14. 14.
    Dirican RM. Community medicine courses (in Turkish). Ankara:Hatipoglu Yayinevi;1990. 1012.Google Scholar
  15. 15.
    Edirne T, Bloom P, Ersoy F. Update on family medicine in Turkey. Fam Med. 2004;36:311.PubMedGoogle Scholar
  16. 16.
    White EV. The development of the family prescription record system. J Am Pharm Assoc. 1973;13:357–9.PubMedGoogle Scholar
  17. 17.
    White EV, Latif DA. Reengineering pharmacotherapy delivery to maximize the role of the pharmacist and improve patient outcomes. Res Social Adm Pharm. 2007;3:223–35.PubMedGoogle Scholar
  18. 18.
    American Pharmaceutical Association. Principles of practice for pharmaceutical care. Washington, DC: American Pharmaceutical Association; 1995.Google Scholar
  19. 19.
    Paquette-Lamontagne N, McLean WM, Besse L, Cusson J. Evaluation of a new integrated discharge prescription form. Ann Pharmacother. 2001;35:953–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Kelly J, Forrest F, Hudson S. A patient-held medication record and a patient medication profile to support the continuity of acute cancer care. Int J Pharm Pract. 2001;9(suppl):R40.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Sule Apikoglu Rabus
    • 1
  • Fikret V. Izzettin
    • 1
  • Mesut Sancar
    • 1
  • Osman Karakaya
    • 2
  • Ramazan Kargin
    • 2
  • Cevat Yakut
    • 3
  1. 1.Clinical Pharmacy Department, Faculty of PharmacyMarmara UniversityIstanbulTurkey
  2. 2.Cardiology DepartmentKosuyolu Heart and Research HospitalIstanbulTurkey
  3. 3.Cardiovascular Surgery DepartmentKosuyolu Heart and Research HospitalIstanbulTurkey

Personalised recommendations